Changeflow GovPing Healthcare & Life Sciences Adeno-Associated Virus Variant Patent Application
Routine Rule Added Final

Adeno-Associated Virus Variant Patent Application

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260109956A1 on April 23, 2026, disclosing an adeno-associated virus 2 (AAV2) variant invented by Dong Woo Song and Hyekyung Oh. The application claims VP1 variants comprising amino acid sequences selected from SEQ ID NOS: 02 to 31. Filing date was October 28, 2025, under application number 19371743. The patent application is classified under CPC codes C12N 7/00 and C07K 14/005, placing it within the biotechnology and gene therapy vector arts.

“An AAV variant according to some embodiments of the present disclosure comprises a VP1 variant comprising having any one amino acid sequence selected from SEQ ID NOS: 02 to 31.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.

What changed

The USPTO published patent application US20260109956A1 disclosing an AAV2 variant comprising VP1 variants with amino acid sequences selected from SEQ ID NOS: 02 to 31. The application was filed on October 28, 2025, and published on April 23, 2026.

For biotechnology companies developing gene therapy products using AAV vectors, this patent application represents prior art that may affect freedom-to-operate analyses. Companies working with AAV2-related technologies should monitor the prosecution of this application to assess potential licensing requirements or design-around strategies.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ADENO-ASSOCIATED VIRUS VARIANT

Application US20260109956A1 Kind: A1 Apr 23, 2026

Inventors

Dong Woo SONG, Hyekyung OH

Abstract

The present disclosure relates to an AAV variant, for example, an AAV2 variant. An AAV variant according to some embodiments of the present disclosure comprises a VP1 variant comprising having any one amino acid sequence selected from SEQ ID NOS: 02 to 31.

CPC Classifications

C12N 7/00 C07K 14/005 C12N 2750/14121 C12N 2750/14122

Filing Date

2025-10-28

Application No.

19371743

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Biotechnology companies Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent application filing Biotechnology research Gene therapy development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!